Results 121 to 130 of about 39,735 (143)

Biomarkers of lung congestion and injury in acute heart failure

ESC Heart Failure, Volume 12, Issue 2, Page 781-789, April 2025.
Abstract Acute heart failure (AHF) classification and management are primarily based on lung congestion and/or hypoperfusion. The quantification of the vascular and tissue lung damage is not standard practice though biomarkers of lung injury may play a relevant role in this context.
Marco Guazzi, Gabriele Novello, Francesca Bursi, Anna Caretti, Noemi Furlotti, Ross Arena, Paola Argiento, Julio Núñez, Antoni Bayes‐Genis, Marco Metra   +9 more
wiley   +1 more source

Role for inflammatory markers in predicting right ventricular failure in mechanical assist device recipients

ESC Heart Failure, EarlyView.
Abstract Right ventricular failure (RVF) is a common complication following left ventricular assist device (LVAD) implantation and increases patient morbidity and mortality. Due to the complex and limited understanding of RVF pathophysiology, efforts to prognosticate RVF after LVAD have been challenging.
Abdul‐Fatawu Osman, Shane S. Scott, Ebubechukwu O. Ezeh, Evans Osuji, Israel O. Ailemen, Mohamed H. Derbala, Salil Kumar, Asvin M. Ganapathi, Daniel B. Sims, Ashrith Guha, Bryan A. Whitson, Sakima A. Smith   +11 more
wiley   +1 more source

New cardiovascular biomarkers in patients with advanced cancer – A prospective study comparing MR‐proADM, MR‐proANP, copeptin, high‐sensitivity troponin T and NT‐proBNP

European Journal of Heart Failure, EarlyView.
(A) Univariable receiver operating characteristic (ROC) curves for all biomarkers. (B) Kaplan–Meier curves for best cut‐point of mid‐regional pro‐adrenomedullin (MR‐proADM) for survival (n = 442). AUC, area under the curve; CI, confidence interval; HR, hazard ratio; hsTnT, high‐sensitivity troponin T; MR‐proANP, mid‐regional pro‐atrial natriuretic ...
Markus S. Anker, Laura C. Lück, Muhammad Shahzeb Khan, Jan Porthun, Sara Hadzibegovic, Alessia Lena, Ursula Wilkenshoff, Pia Weinländer, Ruben Evertz, Matthias Totzeck, Amir A. Mahabadi, Tienush Rassaf, Stefan D. Anker, Lars Bullinger, Ulrich Keller, Mahir Karakas, Ulf Landmesser, Javed Butler, Stephan von Haehling   +18 more
wiley   +1 more source

Proteomic biomarkers and pathway analysis for progression to heart failure in three epidemiological representative cohorts

European Journal of Heart Failure, EarlyView.
Markers of progression to heart failure (HF). Gal‐4, galectin‐4; GDF‐15, growth differentiation factor 15; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide; ST2, suppression of tumorigenicity‐2. ABSTRACT Aims Biomarkers associated with asymptomatic ventricular dysfunction might improve risk stratification and identify pathways leading to heart ...
Anna Dieden, Nicolas Girerd, Filip Ottosson, John Molvin, Manan Pareek, Olle Melander, Erasmus Bachus, Lennart Råstam, Ulf Lindblad, Bledar Daka, Margrét Leósdóttir, Peter M. Nilsson, Michael H. Olsen, Andrew L. Clark, John G.F. Cleland, Christian Delles, Arantxa González, Zohra Lamiral, Kevin Duarte, Patrick Rossignol, Faiez Zannad, Petri Gudmundsson, Amra Jujić, Martin Magnusson   +23 more
wiley   +1 more source

Current and novel biomarkers in cardiogenic shock

European Journal of Heart Failure, EarlyView.
A summary of current and novel biomarkers and their potential stages of release in cardiogenic shock. The diagram illustrates the proposed release of the biomarkers during the different stages of cardiogenic shock: progression from cardiac dysfunction/stress, through to inflammation and end‐organ dysfunction.
Victor Galusko, Florian A. Wenzl, Christophe Vandenbriele, Vasileios Panoulas, Thomas F. Lüscher, Diana A. Gorog   +5 more
wiley   +1 more source

Update on preclinical models of cancer therapy‐related cardiac dysfunction: Challenges and perspectives. A scientific statement of the Heart Failure Association (HFA) of the ESC, the ESC Council of Cardio‐Oncology, and the ESC Working Group on Cellular Biology of the Heart

European Journal of Heart Failure, EarlyView.
New anticancer therapies with potential cardiovascular side effects are continuously being introduced into clinical practice, with new and often unexpected toxicities becoming apparent only after clinical introduction. These unknown toxicities should be identified and understood beforehand to better prepare patients and physicians, enabling the ...
Alessandra Ghigo, Pietro Ameri, Aarti Asnani, Edoardo Bertero, Rudolf A. de Boer, Dimitrios Farmakis, Arantxa González, Stephane Heymans, Borja Ibáñez, Teresa López‐Fernández, Alexander R. Lyon, Piero Pollesello, Amina Rakisheva, Konstantinos Stellos, Katrin Streckfuss‐Bömeke, Carlo Gabriele Tocchetti, Thomas Thum, Peter van der Meer, Eva Van Rooij, Piotr Ponikowski, Marco Metra, Giuseppe Rosano, Sophie Van Linthout   +22 more
wiley   +1 more source

Exploring the Potential of Liposomal Delivery of Naringenin and Berberine for Browning Adipose Tissue and Obesity Management

European Journal of Lipid Science and Technology, EarlyView.
Biocompatible and biodegradable liposomes were developed to encapsulate naringenin (N) and berberine (B), enhancing their stability and bioavailability. Their effects on thermogenesis and browning in 3T3‐L1 preadipocyte cells compared to their free forms were investigated.
Elif Didem Örs Demet, Kübra Uçar Baş, Aslıhan Alpaslan, Dilem Tuğal Aslan, Tuba Reçber, Tuğba Gülsün, Mustafa Çelebier, Zeynep Göktaş   +7 more
wiley   +1 more source

Consensus findings of an International Workshops on Genotoxicity Testing workshop on using transcriptomic biomarkers to predict genotoxicity

Environmental and Molecular Mutagenesis, EarlyView.
Abstract Gene expression biomarkers have the potential to identify genotoxic and non‐genotoxic carcinogens, providing opportunities for integrated testing and reducing animal use. In August 2022, an International Workshops on Genotoxicity Testing (IWGT) workshop was held to critically review current methods to identify genotoxicants using ...
Roland Froetschl, J. Christopher Corton, Henghong Li, Jiri Aubrecht, Scott S. Auerbach, Florian Caiment, Tatyana Y. Doktorova, Yurika Fujita, Danyel Jennen, Naoki Koyama, Matthew J. Meier, Roman Mezencev, Leslie Recio, Takayoshi Suzuki, Carole L. Yauk   +14 more
wiley   +1 more source

NIR II‐Guided Photoactivatable Silencing Polyplex Boosts Cancer Immunotherapy

Exploration, EarlyView.
Due to limitation of penetration therapy with first and second‐generation photodynamic therapy (PDT) photosensitizers, an NIR II‐guided photoactivatable complex was proposed via the self‐assembly of the photosensitive polymer PTSQ and the electrostatic adsorption of siPD‐L1 to enhance cancer immunotherapy.
Yuquan Zhang, Jie Wang, Tian Zhang, Dongsheng Tang, Haiyin Yang, Shuai Guo, Yuchuan Fan, Caixia Sun, Haihua Xiao, Yuanyu Huang, Yuhua Weng   +10 more
wiley   +1 more source

STIP1 drives Metabolic Reprogramming in Esophageal Squamous Cell Carcinoma via AHCY‐LDHA Axis

Exploration, EarlyView.
A schematic model illustrating that LCA can inhibit ESCC growth by inhibiting the STIP1/AHCY/LDHA axis. In brief. Jin et al. demonstrated that targeting STIP1 can significantly inhibit the progression of esophageal squamous cell carcinoma. The high expression of STIP1 increased the interaction between AHCY and LDHA and then AHCY recruits PRMT3 to ...
Guoguo Jin, Yanming Song, Mingyang Yan, Shaobo Fang, Yang Shao, Kexin Zhao, Meng Liu, Qinxin Guo, Xinyang Jia, Chengjuan Zhang, Zhenwei Wang, Kangdong Liu, Xiang Li, Simin Zhao, Mee‐Hyun Lee, Zhiping Guo, Zigang Dong   +16 more
wiley   +1 more source